US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
IL47062A
(en)
|
1975-04-10 |
1979-07-25 |
Yeda Res & Dev |
Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
|
US4665077A
(en)
|
1979-03-19 |
1987-05-12 |
The Upjohn Company |
Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
US5811310A
(en)
|
1986-09-30 |
1998-09-22 |
Albert Einstein College Of Medicine Of Yeshiva Univ. |
The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
|
US6893625B1
(en)
|
1986-10-27 |
2005-05-17 |
Royalty Pharma Finance Trust |
Chimeric antibody with specificity to human B cell surface antigen
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
US5231000A
(en)
|
1987-10-08 |
1993-07-27 |
The Mclean Hospital |
Antibodies to A4 amyloid peptide
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US4892538A
(en)
|
1987-11-17 |
1990-01-09 |
Brown University Research Foundation |
In vivo delivery of neurotransmitters by implanted, encapsulated cells
|
US5283187A
(en)
|
1987-11-17 |
1994-02-01 |
Brown University Research Foundation |
Cell culture-containing tubular capsule produced by co-extrusion
|
WO1989008114A1
(en)
|
1988-02-25 |
1989-09-08 |
The General Hospital Corporation |
Rapid immunoselection cloning method
|
US5506126A
(en)
|
1988-02-25 |
1996-04-09 |
The General Hospital Corporation |
Rapid immunoselection cloning method
|
IL85746A
(en)
|
1988-03-15 |
1994-05-30 |
Yeda Res & Dev |
Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
|
US4861579A
(en)
|
1988-03-17 |
1989-08-29 |
American Cyanamid Company |
Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
|
FI891226A
(fi)
|
1988-04-28 |
1989-10-29 |
Univ Leland Stanford Junior |
Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
|
WO1990008187A1
(en)
|
1989-01-19 |
1990-07-26 |
Dana Farber Cancer Institute |
Soluble two domain cd2 protein
|
JP3472297B2
(ja)
|
1989-03-21 |
2003-12-02 |
ザ イミューン レスポンス コーポレイション |
特定のt細胞集団の病原性応答により生じる疾患に対するワクチン接種および方法
|
CA2064077C
(en)
|
1989-07-19 |
2002-03-12 |
Arthur A. Vandenbark |
T cell receptor peptides as therapeutics for autoimmune and malignant disease
|
US5154924A
(en)
|
1989-09-07 |
1992-10-13 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
NZ236819A
(en)
|
1990-02-03 |
1993-07-27 |
Max Planck Gesellschaft |
Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
JP2780507B2
(ja)
|
1991-03-29 |
1998-07-30 |
松下電器産業株式会社 |
内燃機関用フィルタ再生装置
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
EP0861893A3
(en)
|
1991-09-19 |
1999-11-10 |
Genentech, Inc. |
High level expression of immunoglobulin polypeptides
|
EP0614375A1
(en)
|
1991-11-26 |
1994-09-14 |
Alkermes, Inc. |
Process for the preparation of transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
WO1993025673A1
(en)
|
1992-06-04 |
1993-12-23 |
The Regents Of The University Of California |
In vivo gene therapy with intron-free sequence of interest
|
ATE191853T1
(de)
|
1992-07-27 |
2000-05-15 |
Us Health |
Zielgerichte liposome zur blut-hirne schranke
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US7744877B2
(en)
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
DE69329503T2
(de)
|
1992-11-13 |
2001-05-03 |
Idec Pharma Corp |
Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
ATE239797T1
(de)
|
1993-01-25 |
2003-05-15 |
Takeda Chemical Industries Ltd |
Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
|
US5955317A
(en)
|
1993-01-25 |
1999-09-21 |
Takeda Chemical Industries, Ltd. |
Antibodies to β-amyloids or their derivatives and use thereof
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
US5417972A
(en)
|
1993-08-02 |
1995-05-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
|
US5595721A
(en)
|
1993-09-16 |
1997-01-21 |
Coulter Pharmaceutical, Inc. |
Radioimmunotherapy of lymphoma using anti-CD20
|
US5443953A
(en)
|
1993-12-08 |
1995-08-22 |
Immunomedics, Inc. |
Preparation and use of immunoconjugates
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5910486A
(en)
|
1994-09-06 |
1999-06-08 |
Uab Research Foundation |
Methods for modulating protein function in cells using, intracellular antibody homologues
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US5688651A
(en)
|
1994-12-16 |
1997-11-18 |
Ramot University Authority For Applied Research And Development Ltd. |
Prevention of protein aggregation
|
US5586553A
(en)
|
1995-02-16 |
1996-12-24 |
Minimed Inc. |
Transcutaneous sensor insertion set
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US6015555A
(en)
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
CN1191606A
(zh)
|
1995-06-06 |
1998-08-26 |
干细胞治疗公司 |
BL3造血干细胞上的糖蛋白gp105
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
EP1516628B1
(en)
|
1995-07-27 |
2013-08-21 |
Genentech, Inc. |
Stable isotonic lyophilized protein formulation
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
DE19528388A1
(de)
|
1995-08-02 |
1997-02-06 |
Hans Peter Prof Dr Med Zenner |
Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
|
ATE219517T1
(de)
|
1995-08-18 |
2002-07-15 |
Morphosys Ag |
Protein-/(poly)peptidbibliotheken
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
US20010056066A1
(en)
|
1996-07-26 |
2001-12-27 |
Smithkline Beecham Corporation |
Method of treating immune cell mediated systemic diseases
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
JP3919235B2
(ja)
|
1997-06-13 |
2007-05-23 |
ジェネンテク,インコーポレイテッド |
抗体製剤
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
EP0994903B1
(en)
|
1997-06-24 |
2005-05-25 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
US6368596B1
(en)
|
1997-07-08 |
2002-04-09 |
Board Of Regents, The University Of Texas System |
Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
AU759779B2
(en)
|
1997-10-31 |
2003-05-01 |
Genentech Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
BR9813365A
(pt)
|
1997-12-05 |
2004-06-15 |
Scripps Research Inst |
Método para produção e humanização de um anticorpo monoclonal de rato
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
DK2180007T4
(da)
|
1998-04-20 |
2017-11-27 |
Roche Glycart Ag |
Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
|
EA004107B1
(ru)
|
1998-08-11 |
2003-12-25 |
Айдек Фармацевтикалс Корпорэйшн |
Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
|
US6224866B1
(en)
|
1998-10-07 |
2001-05-01 |
Biocrystal Ltd. |
Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
|
SK287491B6
(sk)
|
1998-10-16 |
2010-11-08 |
Biogen Idec Ma Inc. |
Fúzne proteíny interferónu- beta-1a a ich použitie
|
AU761844C
(en)
|
1998-11-09 |
2004-09-23 |
F. Hoffmann-La Roche Ag |
Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
|
ATE454166T1
(de)
|
1998-11-09 |
2010-01-15 |
Biogen Idec Inc |
Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6897044B1
(en)
|
1999-01-28 |
2005-05-24 |
Biogen Idec, Inc. |
Production of tetravalent antibodies
|
EP1035172A3
(en)
|
1999-03-12 |
2002-11-27 |
Fuji Photo Film Co., Ltd. |
Azomethine compound and oily magenta ink
|
PT1176195E
(pt)
|
1999-04-09 |
2013-07-18 |
Kyowa Hakko Kirin Co Ltd |
Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
|
IL129427A0
(en)
|
1999-04-13 |
2000-02-17 |
Yeda Res & Dev |
Preparation of biologically active molecules
|
SE9901428D0
(sv)
|
1999-04-21 |
1999-04-21 |
Karolinska Innovations Ab |
Amphibodies
|
DK1176981T3
(da)
|
1999-05-07 |
2006-04-10 |
Genentech Inc |
Behandling af autoimmune sygdomme med antagonister som binder til B celleoverflademarkörer
|
US7074403B1
(en)
|
1999-06-09 |
2006-07-11 |
Immunomedics, Inc. |
Immunotherapy of autoimmune disorders using antibodies which target B-cells
|
ITMI991299A1
(it)
|
1999-06-11 |
2000-12-11 |
Consiglio Nazionale Ricerche |
Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
|
US6582945B1
(en)
|
1999-06-16 |
2003-06-24 |
Boston Biomedical Research Institute |
Immunological control of β-amyloid levels in vivo
|
DE19930748C2
(de)
|
1999-07-02 |
2001-05-17 |
Infineon Technologies Ag |
Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
|
CN101264324A
(zh)
|
1999-07-12 |
2008-09-17 |
杰南技术公司 |
应用结合cd20的拮抗剂阻断对外来抗原的免疫应答
|
US6451284B1
(en)
|
1999-08-11 |
2002-09-17 |
Idec Pharmaceuticals Corporation |
Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
|
CA2378646A1
(en)
|
1999-08-11 |
2001-02-15 |
Idec Pharmaceuticals Corporation |
Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
AU6929100A
(en)
|
1999-08-23 |
2001-03-19 |
Biocrystal Limited |
Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
|
KR100797667B1
(ko)
|
1999-10-04 |
2008-01-23 |
메디카고 인코포레이티드 |
외래 유전자의 전사를 조절하는 방법
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
AU7950400A
(en)
|
1999-10-19 |
2001-04-30 |
Kyowa Hakko Kogyo Co. Ltd. |
Process for producing polypeptide
|
EP1229935A1
(en)
|
1999-11-08 |
2002-08-14 |
Idec Pharmaceuticals Corporation |
Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
|
US20020006404A1
(en)
|
1999-11-08 |
2002-01-17 |
Idec Pharmaceuticals Corporation |
Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
IL149924A0
(en)
|
1999-11-29 |
2002-11-10 |
Neurochem Inc |
Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
|
US20020094335A1
(en)
|
1999-11-29 |
2002-07-18 |
Robert Chalifour |
Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
|
JP2003531821A
(ja)
|
1999-12-29 |
2003-10-28 |
イムノージェン インコーポレーテッド |
改変型ドキソルビシンおよびダウノルビシンを含む細胞傷害性薬剤ならびにその治療上の使用
|
US20020127652A1
(en)
|
2000-02-11 |
2002-09-12 |
Schambye Hans Thalsgard |
Follicle stimulating hormones
|
EP1125905A1
(en)
|
2000-02-16 |
2001-08-22 |
Pepscan Systems B.V. |
Segment synthesis
|
EP1267927A1
(en)
|
2000-03-24 |
2003-01-02 |
Chiron Corporation |
Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2
|
US20030185796A1
(en)
|
2000-03-24 |
2003-10-02 |
Chiron Corporation |
Methods of therapy for non-hodgkin's lymphoma
|
AU8729101A
(en)
|
2000-03-31 |
2001-10-15 |
Idec Pharma Corp |
Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for the treatment of B cell lymphoma
|
DK2857516T3
(en)
|
2000-04-11 |
2017-08-07 |
Genentech Inc |
Multivalent antibodies and uses thereof
|
JP2003531178A
(ja)
|
2000-04-25 |
2003-10-21 |
アイデック ファーマスーティカルズ コーポレイション |
中枢神経系リンパ腫治療用のリツキシマブのクモ膜下投与
|
EP2052742A1
(en)
|
2000-06-20 |
2009-04-29 |
Biogen Idec Inc. |
Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
|
AU7013401A
(en)
|
2000-06-22 |
2002-01-02 |
Univ Iowa Res Found |
Methods for enhancing antibody-induced cell lysis and treating cancer
|
EP1299535A2
(en)
|
2000-06-30 |
2003-04-09 |
Maxygen Aps |
Peptide extended glycosylated polypeptides
|
IL153764A0
(en)
|
2000-07-12 |
2003-07-06 |
Idec Pharma Corp |
Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
|
US20030148404A1
(en)
|
2000-07-27 |
2003-08-07 |
Ramot University Authority For Applied Research & Industrial Development Ltd. |
Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
|
CA2313828A1
(en)
|
2000-08-01 |
2002-02-01 |
Institut De Recherches Cliniques De Montreal/Ircm |
Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production
|
JP2004508420A
(ja)
|
2000-09-18 |
2004-03-18 |
アイデック ファーマスーティカルズ コーポレイション |
B細胞枯渇抗体/免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
EP3263702A1
(en)
|
2000-10-06 |
2018-01-03 |
Kyowa Hakko Kirin Co., Ltd. |
Cells producing antibody compositions
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
AU2002213357A1
(en)
|
2000-10-20 |
2002-05-06 |
Idec Pharmaceuticals Corporation |
Variant igg3 rituxan r and therapeutic use thereof
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
KR100857943B1
(ko)
|
2000-11-30 |
2008-09-09 |
메다렉스, 인코포레이티드 |
인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
|
TWI255272B
(en)
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
JP2005501220A
(ja)
|
2000-12-19 |
2005-01-13 |
パラチン テクノロジーズ インク. |
ペプチドおよび蛋白質の標的特異的折りたたみ部位の識別
|
KR20100031769A
(ko)
|
2000-12-28 |
2010-03-24 |
알투스 파마슈티컬스 인코포레이티드 |
전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
|
US7319139B2
(en)
|
2001-01-29 |
2008-01-15 |
Biogen Idec, Inc. |
TAG-72 specific CH2 domain deleted antibodies
|
CN1494553A
(zh)
|
2001-01-29 |
2004-05-05 |
IDECҩ�﹫˾ |
改变的抗体及其使用方法
|
US20030103971A1
(en)
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
JP2005500018A
(ja)
|
2001-04-02 |
2005-01-06 |
アイデック ファーマスーティカルズ コーポレイション |
GnTIIIと同時発現する組換え抗体
|
ATE507839T1
(de)
|
2001-04-02 |
2011-05-15 |
Genentech Inc |
Kombinationstherapie
|
US7318923B2
(en)
|
2001-04-30 |
2008-01-15 |
Eli Lilly And Company |
Humanized anti-βantibodies
|
DE60229051D1
(de)
|
2001-04-30 |
2008-11-06 |
Lilly Co Eli |
Humanisierte antikörper
|
DE10121982B4
(de)
|
2001-05-05 |
2008-01-24 |
Lts Lohmann Therapie-Systeme Ag |
Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
|
WO2003061694A1
(en)
|
2001-05-10 |
2003-07-31 |
Seattle Genetics, Inc. |
Immunosuppression of the humoral immune response by anti-cd20 antibodies
|
AU2002315168A1
(en)
|
2001-06-14 |
2003-01-02 |
Intermune, Inc. |
Combination therapy of gamma-interferon and b cell specific antibodies
|
US7321026B2
(en)
|
2001-06-27 |
2008-01-22 |
Skytech Technology Limited |
Framework-patched immunoglobulins
|
DE60235013D1
(de)
|
2001-07-25 |
2010-02-25 |
Facet Biotech Corp |
Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
|
MXPA04001072A
(es)
|
2001-08-03 |
2005-02-17 |
Glycart Biotechnology Ag |
Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada.
|
DK1944040T3
(da)
|
2001-08-17 |
2012-10-29 |
Univ Washington |
Analysefremgangsmåde for Alzheimers sygdom
|
EP1432444A4
(en)
|
2001-08-17 |
2005-11-02 |
Lilly Co Eli |
ANTI-BETA ANTIBODIES
|
DE60233744D1
(de)
|
2001-09-20 |
2009-10-29 |
Univ Texas |
Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper-komplexe mit elisa-tests
|
KR100988949B1
(ko)
|
2001-10-25 |
2010-10-20 |
제넨테크, 인크. |
당단백질 조성물
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
CA2469045A1
(en)
|
2001-12-07 |
2003-06-19 |
Chiron Corporation |
Methods of therapy for non-hodgkin's lymphoma
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
CN101914158A
(zh)
|
2002-02-14 |
2010-12-15 |
免疫医疗公司 |
抗cd 20抗体及其融合蛋白和使用方法
|
AR038568A1
(es)
|
2002-02-20 |
2005-01-19 |
Hoffmann La Roche |
Anticuerpos anti-a beta y su uso
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
US20030180292A1
(en)
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
US20050031613A1
(en)
|
2002-04-09 |
2005-02-10 |
Kazuyasu Nakamura |
Therapeutic agent for patients having human FcgammaRIIIa
|
PL373256A1
(en)
|
2002-04-09 |
2005-08-22 |
Kyowa Hakko Kogyo Co, Ltd. |
Cells with modified genome
|
DE60336548D1
(de)
|
2002-04-09 |
2011-05-12 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
EP1498490A4
(en)
|
2002-04-09 |
2006-11-29 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING ANTIBODY COMPOSITION
|
EP1500400A4
(en)
|
2002-04-09 |
2006-10-11 |
Kyowa Hakko Kogyo Kk |
MEDICAMENT WITH ANTIBODY COMPOSITION
|
EP1498491A4
(en)
|
2002-04-09 |
2006-12-13 |
Kyowa Hakko Kogyo Kk |
METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
|
US20030219818A1
(en)
|
2002-05-10 |
2003-11-27 |
Bohen Sean P. |
Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
|
WO2005056606A2
(en)
|
2003-12-03 |
2005-06-23 |
Xencor, Inc |
Optimized antibodies that target the epidermal growth factor receptor
|
AU2003294210A1
(en)
|
2002-07-31 |
2004-05-04 |
Seattle Genetics, Inc |
Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
AR040778A1
(es)
|
2002-08-06 |
2005-04-20 |
Glaxo Group Ltd |
Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
|
CN102268094A
(zh)
*
|
2002-08-30 |
2011-12-07 |
比奥雷克西斯药物公司 |
被修饰的转铁蛋白抗体的融合蛋白
|
WO2004032868A2
(en)
|
2002-10-09 |
2004-04-22 |
Rinat Neuroscience Corp. |
Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
KR20090088973A
(ko)
|
2002-10-17 |
2009-08-20 |
젠맵 에이/에스 |
Cd20에 대한 인간 모노클로날 항체
|
KR101111477B1
(ko)
|
2002-12-03 |
2012-02-23 |
블랜체트 록펠러 뉴로사이언시즈 인스티튜트 |
치료제와 연결된 콜레스테롤을 포함하는 접합체
|
SI2289936T1
(sl)
|
2002-12-16 |
2017-10-30 |
Genentech, Inc. |
Imunoglobulinske variante in njihove uporabe
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
ZA200507757B
(en)
|
2003-04-04 |
2007-01-31 |
Genentech Inc |
High concentration antibody and protein formulations
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
WO2005035586A1
(ja)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
融合蛋白質組成物
|
AU2004280065A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
|
LT2380911T
(lt)
|
2003-11-05 |
2018-07-10 |
Roche Glycart Ag |
Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija
|
KR101438983B1
(ko)
|
2003-11-06 |
2014-09-05 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
JP2007512846A
(ja)
|
2003-12-04 |
2007-05-24 |
ゼンコー・インコーポレイテッド |
増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
|
CA2561264A1
(en)
*
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
CN1961003B
(zh)
|
2004-03-31 |
2013-03-27 |
健泰科生物技术公司 |
人源化抗TGF-β抗体
|
EP2360186B1
(en)
|
2004-04-13 |
2017-08-30 |
F. Hoffmann-La Roche AG |
Anti-P-selectin antibodies
|
GB0412186D0
(en)
|
2004-05-28 |
2004-06-30 |
Univ Cambridge Tech |
Production of recombinant protein
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
PL1791565T3
(pl)
|
2004-09-23 |
2016-10-31 |
|
Modyfikowane cysteiną przeciwciała i koniugaty
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US7697967B2
(en)
|
2005-12-28 |
2010-04-13 |
Abbott Diabetes Care Inc. |
Method and apparatus for providing analyte sensor insertion
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
RU2007124933A
(ru)
|
2005-01-28 |
2009-03-10 |
Вайет (Us) |
Стабилизированные жидкие полипептидные составы
|
CN105153306B
(zh)
|
2005-06-07 |
2020-12-11 |
艾斯巴技术-诺华有限责任公司 |
抑制TNFα的稳定和可溶的抗体
|
US8053569B2
(en)
|
2005-10-07 |
2011-11-08 |
Armagen Technologies, Inc. |
Nucleic acids encoding and methods of producing fusion proteins
|
JO2824B1
(en)
|
2005-12-12 |
2014-09-15 |
اف . هوفمان لاروش ايه جي |
Antibody glycosylate in the changing region
|
DE102006013531A1
(de)
|
2006-03-24 |
2007-09-27 |
Lts Lohmann Therapie-Systeme Ag |
Polylactid-Nanopartikel
|
EP1998806A1
(en)
|
2006-03-28 |
2008-12-10 |
F. Hoffmann-Roche AG |
Anti-igf-1r human monoclonal antibody formulation
|
EP2035572A4
(en)
|
2006-06-30 |
2010-01-06 |
Univ Michigan |
PROCESS FOR THE PREPARATION OF FACTOR VIII PROTEINS BY RECOMBINATION PROCEDURES
|
US8759297B2
(en)
|
2006-08-18 |
2014-06-24 |
Armagen Technologies, Inc. |
Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
|
CN101484469B
(zh)
|
2006-08-31 |
2012-12-12 |
弗·哈夫曼-拉罗切有限公司 |
生产***-ⅰ的方法
|
US9382327B2
(en)
|
2006-10-10 |
2016-07-05 |
Vaccinex, Inc. |
Anti-CD20 antibodies and methods of use
|
AU2007331712A1
(en)
|
2006-12-11 |
2008-06-19 |
F. Hoffmann-La Roche Ag |
Abeta antibody parenteral formulation
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
US9745367B2
(en)
|
2007-03-23 |
2017-08-29 |
Novelmed Theraputics, Inc. |
Alternative pathway specific antibodies for treating arthritis
|
BRPI0810710A2
(pt)
|
2007-05-02 |
2014-10-21 |
Hoffmann La Roche |
Método para estabilização de uma proteína.
|
US8062864B2
(en)
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
PL2178916T3
(pl)
|
2007-07-31 |
2015-08-31 |
Regeneron Pharma |
Ludzkie przeciwciała przeciwko ludzkiemu CD20 i sposób ich zastosowania
|
US8629246B2
(en)
*
|
2007-09-26 |
2014-01-14 |
Ucb Pharma S.A. |
Dual specificity antibody fusions
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
CA2716738A1
(en)
|
2008-04-07 |
2009-10-15 |
Zymogenetics, Inc. |
Thrombin activator compositions and methods of making and using the same
|
JP2011528605A
(ja)
|
2008-07-21 |
2011-11-24 |
アルスタシス,インコーポレイテッド |
組織内に管を形成するデバイス、方法、及びキット
|
US20100077498A1
(en)
|
2008-09-11 |
2010-03-25 |
Pardridge William M |
Compositions and methods for blood-brain barrier delivery in the mouse
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
AU2009296297A1
(en)
|
2008-09-26 |
2010-04-01 |
Roche Glycart Ag |
Bispecific anti-EGFR/anti-IGF-1R antibodies
|
US20130090457A1
(en)
|
2008-10-31 |
2013-04-11 |
Janssen Biotech, Inc. |
Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases
|
US8323649B2
(en)
|
2008-11-25 |
2012-12-04 |
Alderbio Holdings Llc |
Antibodies to IL-6 and use thereof
|
AR075798A1
(es)
|
2009-03-05 |
2011-04-27 |
Abbott Lab |
Proteinas de union a il-17 (interleuquina 17)
|
JP5501439B2
(ja)
|
2009-04-02 |
2014-05-21 |
ロシュ グリクアート アクチェンゲゼルシャフト |
完全長抗体と単鎖Fabフラグメントとを含む多重特異的抗体
|
BRPI1014449A2
(pt)
|
2009-04-07 |
2017-06-27 |
Roche Glycart Ag |
anticorpos biespecíficos anti-erbb-2/ anti-c-met.
|
US8703132B2
(en)
*
|
2009-06-18 |
2014-04-22 |
Hoffmann-La Roche, Inc. |
Bispecific, tetravalent antigen binding proteins
|
US9775921B2
(en)
|
2009-11-24 |
2017-10-03 |
Alderbio Holdings Llc |
Subcutaneously administrable composition containing anti-IL-6 antibody
|
US9724410B2
(en)
|
2009-11-24 |
2017-08-08 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies or fragments thereof to treat or inhibit cachexia, associated with chemotherapy toxicity
|
FR2953841B1
(fr)
|
2009-12-16 |
2011-12-30 |
Centre Nat Rech Scient |
Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
|
WO2011116387A1
(en)
*
|
2010-03-19 |
2011-09-22 |
Tetragenetics, Inc. |
Production of aglycosylated monoclonal antibodies in ciliates
|
RU2439160C1
(ru)
|
2010-06-25 |
2012-01-10 |
Государственное общеобразовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) |
Способ получения моноклональных антител к аблюминальному мембранному антигену церебральных эндотелиоцитов
|
BR112013002578A2
(pt)
*
|
2010-08-03 |
2019-05-14 |
Abbvie Inc. |
imunoglobinas de domínio variável duplo e usos das mesmas
|
EP2646470B1
(en)
*
|
2010-11-30 |
2017-03-01 |
F. Hoffmann-La Roche AG |
Low affinity anti-transferrin receptor antibodies and their use to transfer therapeutic scfv across the blood brain barrier
|
MX359070B
(es)
|
2010-12-01 |
2018-09-13 |
Alderbio Holdings Llc |
Composiciones anti-ngf y uso de las mismas.
|
WO2012087835A2
(en)
|
2010-12-22 |
2012-06-28 |
Boston Biomedical Research Institute |
Compositions and methods for enhancing protein folding
|
SG191762A1
(en)
|
2011-01-06 |
2013-08-30 |
Glaxo Group Ltd |
Ligands that bind tgf-beta receptor ii
|
JP2014506258A
(ja)
*
|
2011-01-10 |
2014-03-13 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
新規使用
|
WO2012116453A1
(en)
|
2011-03-03 |
2012-09-07 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
EP3590965A1
(en)
|
2011-03-29 |
2020-01-08 |
Roche Glycart AG |
Antibody fc variants
|
CA2828662A1
(en)
|
2011-04-20 |
2012-10-26 |
Roche Glycart Ag |
Method and constructs for the ph dependent passage of the blood-brain-barrier
|
CA2835603A1
(en)
|
2011-05-09 |
2012-11-15 |
Perseus Proteomics Inc. |
Antibody capable of specifically recognizing transferrin receptor
|
EP2701675A1
(en)
|
2011-07-08 |
2014-03-05 |
Biosynthetic Technologies, LLC |
Compositions and products containing estolide compounds
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
BR112014003431A2
(pt)
|
2011-08-17 |
2017-06-13 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
|
LT2748201T
(lt)
*
|
2011-08-23 |
2018-02-26 |
Roche Glycart Ag |
Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
|
EP2748202B1
(en)
|
2011-08-23 |
2018-07-04 |
Roche Glycart AG |
Bispecific antigen binding molecules
|
PT2758432T
(pt)
|
2011-09-16 |
2019-06-14 |
Ucb Biopharma Sprl |
Anticorpos neutralizantes contra as exotoxinas principais tcda e tcdb de clostridium difficile
|
ES2732712T3
(es)
*
|
2011-10-31 |
2019-11-25 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera
|
JP6138813B2
(ja)
|
2011-11-28 |
2017-05-31 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
抗pd−l1抗体及びその使用
|
RU2693264C2
(ru)
|
2012-02-03 |
2019-07-01 |
Ф.Хоффман-Ля Рош Аг |
Молекулы биспецифических антител и т-клетки, трансфецированные антигеном, и их применение в медицине
|
US20150044718A1
(en)
|
2012-02-29 |
2015-02-12 |
Hoffmann-La Roche Inc. |
On-column enzymatic cleavage
|
BR112014019667B1
(pt)
|
2012-03-08 |
2022-11-01 |
F. Hoffmann-La Roche Ag |
Formulação farmacêutica líquida estável de anticorpo abeta
|
WO2013150043A1
(en)
|
2012-04-05 |
2013-10-10 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against human tweak and human il17 and uses thereof
|
US20150353639A1
(en)
|
2012-05-21 |
2015-12-10 |
Genentech, Inc. |
Methods for improving safety of blood-brain barrier transport
|
EP2668901A1
(en)
|
2012-05-31 |
2013-12-04 |
Roche Diagniostics GmbH |
Sensor insertion assembly, sensor cartridge, and inserter
|
US9438547B2
(en)
|
2012-07-10 |
2016-09-06 |
Microsoft Technology Licensing, Llc |
Uniform policy for security and information protection
|
US9382329B2
(en)
*
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
RS58928B1
(sr)
*
|
2012-08-29 |
2019-08-30 |
Hoffmann La Roche |
Transporter za krvno-moždanu barijeru
|
EP3919079A1
(en)
|
2012-09-07 |
2021-12-08 |
Genentech, Inc. |
Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
JP6324974B2
(ja)
|
2012-10-12 |
2018-05-23 |
アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ |
タウの毒性オリゴマー形態を特異的に認識する抗体ベースの試薬
|
UY35148A
(es)
*
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
KR102264570B1
(ko)
*
|
2012-11-28 |
2021-06-14 |
자임워크스 인코포레이티드 |
가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
|
CA2890455A1
(en)
|
2012-12-04 |
2014-06-12 |
Abbvie, Inc. |
Blood-brain barrier (bbb) penetrating dual specific binding proteins
|
RU2015140917A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
US9481725B2
(en)
|
2013-03-14 |
2016-11-01 |
Alderbio Holdings, Llc |
Antibodies to HGF and compositions containing
|
EP2970500A1
(en)
|
2013-03-14 |
2016-01-20 |
Bayer HealthCare LLC |
Monoclonal antibodies against antithrombin beta complexed with heparin
|
WO2014153114A1
(en)
|
2013-03-14 |
2014-09-25 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to modify cells for therapeutic objectives
|
US9732150B2
(en)
|
2013-03-14 |
2017-08-15 |
Alderbio Holdings Llc |
Therapeutic use of antibodies to HGF
|
DE102013208865A1
(de)
|
2013-05-14 |
2014-11-20 |
Beiersdorf Ag |
Stabilisierte Zubereitungen mit einem Gehalt an Ascorbinsäure und Phosphationen
|
CA2908743A1
(en)
*
|
2013-05-20 |
2014-11-27 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
EP3027280A1
(en)
|
2013-08-02 |
2016-06-08 |
F. Hoffmann-La Roche AG |
Therapeutic fusion protein
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
CN105873953A
(zh)
|
2013-11-04 |
2016-08-17 |
格兰马克药品股份有限公司 |
重靶向t细胞的异源二聚免疫球蛋白的产生
|
AU2014345712B2
(en)
|
2013-11-07 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of an anti CD20 antibody with a BTK inhibitor
|
SI3071597T1
(sl)
|
2013-11-21 |
2020-11-30 |
F. Hoffmann-La Roche Ag |
Anti alfa-sinukleinska protitelesa in postopki uporabe
|
PE20210107A1
(es)
|
2013-12-17 |
2021-01-19 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
CA2929149A1
(en)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Improved recombinant polypeptide production methods
|
CN111057151B
(zh)
|
2014-01-06 |
2022-05-03 |
豪夫迈·罗氏有限公司 |
单价血脑屏障穿梭模块
|
US9629801B2
(en)
|
2014-01-10 |
2017-04-25 |
Wisconsin Alumni Research Foundation |
Blood-brain barrier targeting antibodies
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
MA50584A
(fr)
|
2014-08-04 |
2020-09-16 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène activant des lymphocytes t
|
EP3223845B1
(en)
|
2014-11-26 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd20
|
WO2016160032A1
(en)
|
2015-04-03 |
2016-10-06 |
Entropic Communications, Inc. |
Low power adc with pulsed bias
|
US20160297581A1
(en)
|
2015-04-13 |
2016-10-13 |
Aplix Inc |
Closable container
|
CA2990785A1
(en)
|
2015-06-24 |
2016-12-29 |
Jcr Pharmaceuticals Co., Ltd. |
Anti-human transferrin receptor antibody permeating blood-brain barrier
|
RU2020124105A
(ru)
|
2015-06-24 |
2020-09-18 |
Ф. Хоффманн-Ля Рош Аг |
Антитела против трансферринового рецептора, обладающие индивидуализированной аффинностью
|
CN107531788B
(zh)
|
2015-06-24 |
2022-06-21 |
豪夫迈·罗氏有限公司 |
对her2和血脑屏障受体特异性的三特异性抗体及使用方法
|
CR20180149A
(es)
|
2015-10-02 |
2018-04-05 |
Hoffmann La Roche |
Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
JP2017187722A
(ja)
|
2016-04-08 |
2017-10-12 |
株式会社リコー |
画像濃度検出装置及び画像形成装置
|
WO2018162517A1
(en)
*
|
2017-03-10 |
2018-09-13 |
F. Hoffmann-La Roche Ag |
Method for producing multispecific antibodies
|